| Lifetime Health Medical Group | |
|
800 Carter St, Rochester, NY 14621-2604 | |
| (585) 338-1400 | |
| (585) 336-4845 |
| Full Name | Lifetime Health Medical Group |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 800 Carter St, Rochester, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134272776 | NPI | - | NPPES |
| G0185419597 | Other | NY | GROUP NUMBER FOR BILLING |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lifetime Health Medical Group 800 Carter St, Rochester, NY 14621-2604 Ph: (585) 338-1400 | Lifetime Health Medical Group 800 Carter St, Rochester, NY 14621-2604 Ph: (585) 338-1400 |
News Archive
Today's headlines highlight news regarding President Obama's planned summit on health care - Republicans will be invited.
Use of nonsteroidal anti-inflammatory drugs is associated with a decreased risk for skin cancer, particularly squamous cell carcinoma and malignant melanoma, study findings indicate.
Exploration of new leukemia antigens and construction of appropriate delivery systems using FDA-approved material are important strategies for developing leukemia vaccines for clinic use.
Oral bisphosphonates are common first line treatments for osteoporosis. However, approximately half of patients who begin osteoporosis treatment do not follow their prescribed treatment and/or discontinue treatment within a year.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
› Verified 7 days ago